Education
About Us
Working with TipRanks
Follow Us
Perspective Therapeutics (CATX)
:CATX
CATX Stock Chart & Stats
$5.27
-$0.13(-3.36%)
At close: 4:00 PM EST
$5.27
-$0.13(-3.36%)
Day’s Range― - ―
52-Week Range$1.60 - $6.16
Previous CloseN/A
Volume311.62K
Average Volume (3M)5.42M
Market Cap
$600.33M
Enterprise Value$368.23M
Total Cash (Recent Filing)$174.14M
Total Debt (Recent Filing)$3.31M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Mar 26, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding113,914,080
10 Day Avg. Volume2,018,749
30 Day Avg. Volume5,416,872
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.71
Price to Sales (P/S)0.00
P/FCF Ratio-2.83
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue437.85
Enterprise Value/Gross Profit-263.21
Enterprise Value/Ebitda-3.50
Forecast
1Y Price Target
$13.50Price Target Upside156.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.23
Revenue Forecast (FY)$986.03K
Bulls Say, Bears Say
Bulls Say
Clinical Safety And EfficacyAnalyst highlights that clinical data for the lead radiotherapeutic show objective tumor responses for many treated patients and a favorable safety profile with no treatment-related serious adverse events, supporting the therapy's clinical potential.
Competitive LandscapeSanofi's decision to deprioritize a competing lead-based radiopharmaceutical reduces direct competition for the company's somatostatin receptor-targeted therapy, improving commercial and development prospects.
Manufacturing And Strategic ValueCompany manufacturing investments aim to create excess production capacity that could support clinical programs and enhance attractiveness as a partner or acquisition target in radiopharma dealmaking.
Bears Say
Investor Sentiment And Market VolatilityElevated short interest and a valuation overhang from comparisons with a competitor may increase share price volatility and present downside risk for investors.
Isotope Logistics And AdoptionLogistical challenges and isotope supply constraints represent obstacles that could impede wider clinical adoption and complicate development execution for radiopharmaceutical therapies.
Safety UncertaintySafety uncertainties persist because hair loss, potential kidney effects, and swallowing difficulties have been identified as risks and larger studies are needed to confirm the therapy's safety profile.
Perspective Therapeutics News
CATX FAQ
What was Perspective Therapeutics’s price range in the past 12 months?
Perspective Therapeutics lowest stock price was $1.60 and its highest was $6.16 in the past 12 months.
What is Perspective Therapeutics’s market cap?
Perspective Therapeutics’s market cap is $600.33M.
When is Perspective Therapeutics’s upcoming earnings report date?
Perspective Therapeutics’s upcoming earnings report date is Mar 26, 2026 which is in 21 days.
How were Perspective Therapeutics’s earnings last quarter?
Perspective Therapeutics released its earnings results on Nov 10, 2025. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.321 by -$0.029.
Is Perspective Therapeutics overvalued?
According to Wall Street analysts Perspective Therapeutics’s price is currently Undervalued.
Does Perspective Therapeutics pay dividends?
Perspective Therapeutics does not currently pay dividends.
What is Perspective Therapeutics’s EPS estimate?
Perspective Therapeutics’s EPS estimate is -0.36.
How many shares outstanding does Perspective Therapeutics have?
Perspective Therapeutics has 113,914,080 shares outstanding.
What happened to Perspective Therapeutics’s price movement after its last earnings report?
Perspective Therapeutics reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.321. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Perspective Therapeutics?
Currently, no hedge funds are holding shares in CATX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Perspective Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.50 (156.17% Upside)
$13.50 (156.17% Upside)
Blogger Sentiment
Bullish
CATX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 34.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
110.16%
12-Months-Change
Fundamentals
Return on Equity
-37.24%
Trailing 12-Months
Asset Growth
-24.63%
Trailing 12-Months
Company Description
Perspective Therapeutics
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
CATX Stock 12 Month Forecast
Average Price Target
$13.50
▲(156.17% Upside)
Technical Analysis
Ownership Overview
1.66% Insiders
8.51% Mutual Funds
4.12% Other Institutional Investors
80.22% Public Companies and
Individual Investors